Piper Sandler lowered the firm’s price target on Elanco to $11 from $13 following animal health survey, while keeping a Neutral rating on the shares. Piper is taking down its Q4 numbers slightly to reflect foreign exchange impacts, and its 2024 estimates to reflect potential recessionary impacts.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ELAN:
- Elanco ‘vulnerable to an activist,’ Dealreporter says
- Elanco announces process to amend corporate governing documents
- Elanco says first shipments of Varenzin-CA1 conditionally approved by FDA
- Elanco price target raised to $13 from $9 at Piper Sandler
- Elanco (NYSE:ELAN) Gains On Robust Q2 Showing; Boosts Guidance